Patents Examined by Sudhakar Katakam
  • Patent number: 10538479
    Abstract: Subject-matter of the invention is a process for the preparation of key intermediates in the synthesis of indacaterol. Subject-matter of the invention are also new synthesis intermediates.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 21, 2020
    Assignee: OLON S.P.A.
    Inventors: Corrado Colli, Alessandro Agosti, Stefano Maiorana, Federica Colombo, Giorgio Bertolini
  • Patent number: 10538483
    Abstract: The present invention provides a method of producing an ethanolamine, with a low production ratio of a dialkanolamine (for example, less than 30% by weight). A process for producing an alkanolamine of the present invention includes reacting an alkylene oxide with ammonia to obtain a reaction product containing a monoalkanolamine, a dialkanolamine, and a trialkanolamine; separating the dialkanolamine from the reaction product; and recycling at least a portion of the dialkanolamine for the reaction of an alkylene oxide with ammonia, wherein in the recycling step, the dialkanolamine is supplied in a molar ratio of the alkylene oxide (moles) to a total amount (moles) of ammonia and the dialkanolamine of 0.08 or more and less than 0.26.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: January 21, 2020
    Inventors: Daisuke Ichikawa, Takahiro Sugiya
  • Patent number: 10538481
    Abstract: Provided is a method for purifying 1,5-pentanediamine comprising: providing 1,5-pentanediamine to be purified and treating the 1,5-pentanediamine to be purified by a reduction reaction to obtain purified 1,5-pentanediamine. Meanwhile, further provided is 1,5-pentanediamine prepared by the method. The purification method has a concise process and a simple operation, and is suitable for industrial production, and can significantly improve the quality of 1,5-pentanediamine.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: January 21, 2020
    Assignees: Cathay Biotech Inc., CIBT America Inc.
    Inventors: Bingbing Qin, Charlie Liu, Shanshi Guo, Benliang Hou, Xiucai Liu
  • Patent number: 10537570
    Abstract: The invention relates to pimobendan for use in a method of reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 21, 2020
    Inventors: Christoph Schummer, Olaf Joens
  • Patent number: 10519106
    Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: December 31, 2019
    Assignee: Toray Industries, Inc.
    Inventors: Yukihiro Nishio, Masashi Yamamoto, Yuko Kubota, Hideyuki Tsutsui, Tomohide Masuda, Keiichi Okimura, Syuji Udagawa, Mie Kaino, Hiroyuki Meguro, Yumiko Sekiya
  • Patent number: 10508075
    Abstract: The present invention provides a process for preparation of trientine dihydrochloride (1) comprising reaction of protected triethylene tetramine with hydrochloric acid in an aqueous system to yield the dihydrochloride salt wherein the formation of inorganic impurities and undesired salts is controlled significantly.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: December 17, 2019
    Inventors: Mukund Gurjar, Shashikant Joshi, Devising Pardeshi, Mangesh Kamble, Lakindrasing Girase, Samit Mehta
  • Patent number: 10511068
    Abstract: The present invention relates to a process for recovering a metal salt of an electrolyte dissolved in a matrix, said process consisting in subjecting the electrolyte to a liquid extraction with water.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 17, 2019
    Inventor: François Metz
  • Patent number: 10501410
    Abstract: The subject of the invention is a process for the preparation of high purity prostaglandin acid of the general formula II wherein the bonds marked with dotted lines represent single or double bonds wherein the double bonds may be cis- or trans oriented, Y represents O or CH2, and R3 stands for a phenyl group which is optionally substituted with CF3, wherein the crude prostaglandin acid of the general formula II is purified by normal phase silicagel chromatography.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: December 10, 2019
    Inventors: Ervin Vajda, Irén Hortobágyi, István Lászlofi, Péter Buzder-Lantos, Gábor Havasi, László Takács, Zsuzsanna Kardos
  • Patent number: 10494350
    Abstract: A process for producing biguanidine salts of formula (III) and s-triazines of formula (V) is described. Therein, R1 and R2 are in each case hydrogen, halogen and alkyl, and R3 and R4 are in each case hydrogen, alkyl, cycloalkyl and aryl.
    Type: Grant
    Filed: September 5, 2016
    Date of Patent: December 3, 2019
    Inventors: Hans-Joachim Ressel, Mark James Ford
  • Patent number: 10485851
    Abstract: An injectable aqueous solution, the pH of which is from 6.0 to 8.0, having at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions have, in addition, a gastrointestinal hormone.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: November 26, 2019
    Assignee: ADOCIA
    Inventors: Alexandre Geissler, Ségoléne Laage, Richard Charvet, Olivier Soula, David Duracher, Grégory Meiffren
  • Patent number: 10479763
    Abstract: The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O?-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O?-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: November 19, 2019
    Inventors: Byoung Young Woo, Ki-Wha Lee, Kwang-Hyun Shin, Miyoung Park, Kyoungmi Jung, Joonho Choi, Gyeyoung Choi, Wonkyung Cho, Young-Ho Park
  • Patent number: 10472324
    Abstract: A compound of the formula (I) or a tautomeric isoform thereof wherein R1 is selected from the group consisting of halogen, nitro, lower alkyl sulfonyl, cyano, trifluromethyl lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, lower alkyl aminosulfonyl, perfluoro lower alkyl, lower alkylthio, hydroxy lower alkyl, alkoxy lower alkyl, lower alkylthio lower alkyl, lower alkylsulfinyl lower alkyl, lower alkylsulfonyl lower alkyl, lower alkylsulfonyl, lower alkanoyl, aroyl, aryl, aryloxy and R2 is selected from the group consisting of hydrogen, alkyl, alkoxy, alkylthio, and alkylcarbonyl, and their non-toxic, pharmaceutically acceptable base addition salts or pro-drugs thereof. The compounds of the invention are useful in the treatment of nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex.
    Type: Grant
    Filed: March 15, 2015
    Date of Patent: November 12, 2019
    Inventors: Birgit Hasse, Guido Koopmans
  • Patent number: 10472320
    Abstract: The present invention relates to a process to prepare N,N?-di(2-hydroxybenzyl) ethylenediamine-N,N?-diacetic acid and salts thereof (HBED) comprising a reaction between formaldehyde, ethylenediamine diacetic acid or a salt thereof (EDDA) and phenol, wherein the reaction mixture contains 0.2 to 1.1 molar equivalents of alkali metal ions on the basis of the molar amount of EDDA and the reaction mixture is processed by a step in which at least part of the organic compounds other than the formed HBED are removed from the reaction mixture, and optionally recycled, during which step at least 50% and up to and including 100% of the alkali metal ions in the reaction mixture are potassium ions, to products obtainable by such process and their use.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: November 12, 2019
    Inventors: Adrianus Maria Reichwein, Hubertus Johannes Jongen, Marjolein Groote
  • Patent number: 10471025
    Abstract: The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: November 12, 2019
    Inventors: Nuno Afonso, Sara Sousa, Rita Vaz, Diana Chapela, Sofia Côrte-Real
  • Patent number: 10463670
    Abstract: Use of the non-peptide NK1 receptor antagonist, preferably Aprepitant, for the treatment of cancer in predetermined doses. The present invention also describes pharmaceutical compositions comprising said agents, alone or in combination with at least one other active principle, for the treatment of cancer.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: November 5, 2019
    Inventor: Manuel Vicente Salinas Martín
  • Patent number: 10464880
    Abstract: The present invention relates to a method for the purification of cadaverine from an aqueous cadaverine salt composition comprising one or more involatile impurities, the method comprising: (1) mixing the aqueous cadaverine salt composition with one or more bases to provide an aqueous cadaverine composition having a pH of at least about 12; (2) distilling or evaporating the aqueous cadaverine composition to produce an aqueous cadaverine solution, wherein one or more solvents are added to the evaporation/distillation system before the evaporation/distillation stops, and the one or more solvents comprise at least one or more high boiling point (HBP) solvents having a boiling point of at least 185° C. (1 atm); and (3) subjecting the aqueous cadaverine solution to one or more rectification steps to provide a cadaverine product.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: November 5, 2019
    Inventors: Xiucai Liu, Charlie Liu, Bingbing Qin, Naiqiang Li, Yang Chen
  • Patent number: 10463717
    Abstract: The invention relates to a composition in the form of an injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: *GpRrGpAaGpC)p ??I characterized in that the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition characterized in that it moreover comprises a prandial insulin.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: November 5, 2019
    Assignee: ADOCIA
    Inventors: David Duracher, Gregory Meiffren, Remi Soula
  • Patent number: 10468722
    Abstract: Processes and reaction mixtures including non-aqueous solvent mixtures are presented. Non-aqueous solvent mixtures including fluoride salt and non-aqueous solvent combinations are provided that possess high fluoride ion concentrations useful for a range of applications, including organic synthesis. Further non-aqueous solvent mixtures are provided including a salt possessing a non-fluoride anion and a non-aqueous solvent that, when contacted with aqueous fluoride-containing reagents, extract fluoride ions to form non-aqueous fluoride-ion solutions possessing high fluoride-ion concentrations. The salts include an organic cation that does not possess a carbon in the ?-position or does not possess a carbon in the ?-position having a bound hydrogen. This salt structure facilitates its ability to be made anhydrous without decomposition. Example anhydrous fluoride salts include (2,2-dimethylpropyl)trimethylammonium fluoride and bis(2,2-dimethylpropyl)dimethylammonium fluoride.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: November 5, 2019
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Simon C. Jones, Victoria K. Davis, Christopher M. Bates, Nebojsa Momcilovic, Brett M. Savoie, Michael A. Webb, Thomas F. Miller, III, Robert H. Grubbs, Jennifer M. Murphy
  • Patent number: 10457706
    Abstract: Water dispersible, multivalent ligand-lipid constructs that spontaneously and stably incorporate into membranes are disclosed.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 29, 2019
    Inventors: Stephen Micheal Henry, Elena Korchagina, Igor Leonidovich Rodionov, Alexander Borisovich Tuzikov
  • Patent number: 10449165
    Abstract: Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 22, 2019
    Inventors: Michael Allio, Jonathan Gordon